Scott Got­tlieb clears an­oth­er hur­dle in last stretch ahead of the FDA; Sanofi inks €250M bis­pe­cif­ic dis­cov­ery deal in meta­bol­ics

→ The Sen­ate vot­ed to end de­bate on Scott Got­tlieb’s nom­i­na­tion to run the FDA, set­ting up a fi­nal vote that is wide­ly ex­pect­ed to con­firm him in the po­si­tion.

→ Scot­land’s Ex­sci­en­tia forged a strate­gic re­search deal with Sanofi cov­er­ing meta­bol­ic dis­ease. Ex­sci­en­tia will go to work look­ing for new bis­pecifics, and Sanofi will pro­vide re­search fund­ing and up to €250 mil­lion in mile­stones. An­drew Hop­kins, CEO, Ex­sci­en­tia said: “We are de­light­ed that Sanofi is en­gag­ing with Ex­sci­en­tia in a com­pre­hen­sive, end-to-end drug dis­cov­ery project. This agree­ment high­lights Ex­sci­en­tia’s abil­i­ty to ap­ply bis­pe­cif­ic drug de­sign in a com­pre­hen­sive and high­ly pro­duc­tive man­ner.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER